Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)

ClinicalTrials.gov ID: NCT06980948

Public ClinicalTrials.gov record NCT06980948. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 20, 2026, 11:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter Phase 1 / 2 Double-blind, Randomized, Sham-controlled Dose Escalation Study to Determine Safety and Tolerability of Single Dose Intrathecal ST-503 Gene Therapy for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)

Study identification

NCT ID: NCT06980948
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Sangamo Therapeutics; Industry
Enrollment: 27 participants

Conditions and interventions

Conditions

Chronic Neuropathic Pain

Interventions

ST-503 Genetic
Sham (No Treatment) Procedure

Genetic · Procedure

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 3, 2025
Primary completion: Jun 30, 2027
Completion: Jun 30, 2028
Last update posted: Apr 29, 2026

2025 – 2028

United States locations

U.S. sites: 11
U.S. states: 11
U.S. cities: 11

Facility	City	State	ZIP	Site status
HonorHealth	Scottsdale	Arizona	85260	Recruiting
University of Arkansas for Medical Sciences	Little Rock	Arkansas	72205	Recruiting
The University of California, San Diego	La Jolla	California	92093	Not yet recruiting
Johns Hopkins University	Baltimore	Maryland	21218	Not yet recruiting
Massachusetts General Hospital	Boston	Massachusetts	02114	Recruiting
Dartmouth Hitchcock Medical Center	Lebanon	New Hampshire	03766	Not yet recruiting
Columbia University Irving Medical Center (CUIMC) and New York-Presbyterian Hospital (NYPH)	New York	New York	10027	Recruiting
University of North Carolina Medical Center	Chapel Hill	North Carolina	27514	Not yet recruiting
Vanderbilt University	Nashville	Tennessee	37235	Not yet recruiting
University of Utah	Salt Lake City	Utah	84112	Not yet recruiting
Virginia Commonwealth University	Richmond	Virginia	23284	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06980948, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 29, 2026 · Synced May 20, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06980948 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →